October 11 2013 – UAB gets $9.7 million to find treatments for deadly lung disease pulmonary fibrosis

UAB gets $9.7 million to find treatments for deadly lung disease pulmonary fibrosis

Grant will allow UAB researchers to study novel therapies for pulmonary fibrosis, a deadly lung disease with no approved treatments.

The University of Alabama at Birmingham Division of Pulmonary, Allergy and Critical Care Medicine has received a $9.7 million grant over five years from the National Institutes of Health to identify and test potential therapies for pulmonary fibrosis, a devastating disease with no approved treatments.

thannickal_grant_s“Fibrosis means scarring, and idiopathic pulmonary fibrosis is a disease of unknown origin that results in scar tissue building up in the lungs,” said Victor Thannickal, M.D., director of the Division of Pulmonary Medicine and the principal investigator for the grant. “IPF affects more than 100,000 people in the United States and five million worldwide. This disease is relentless. The median survival rate is less than three years, and only 20 percent of patients survive five years beyond diagnosis.”

Read the entire article at:

http://www.uab.edu/news/latest/item/3841-uab-gets-97-million-to-find-treatments-for-deadly-lung-disease-pulmonary-fibrosis

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

October 10 2013 – Finding cellular causes of lung-hardening disease

Medical Xpress)—Idiopathic Pulmonary Fibrosis, or IPF, is an incurable lung disease that, over time, turns healthy lung tissue into inflexible scar tissue – hardening the lungs and eventually causing respiratory distress and death. Currently, there is no cure.

Phil Sannes, a professor of cell biology, studies IPF on the cellular level. In his most recent research, he’s found that in the case of IPF patients, three growth factors within different types of cells in the lung may be working together to cause the disease.

Previous research, including earlier studies from Sannes’ lab, established two signaling molecules that seemed to be involved in the development of IPF: Wnt7B and TGF-?.

Read the entire article at:

http://medicalxpress.com/news/2013-09-cellular-lung-hardening-disease.html

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

October 9 2013- Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is advancing PRM-151, a recombinant form of an endogenous human protein that offers the potential to prevent and potentially reverse fibrosis. The Phase 2 clinical study of PRM-151 in patients with myelofibrosis, which is expected to complete in 2014, expands Promedior’s clinical focus beyond IPF to myelofibrosis, another serious, life-limiting orphan disease with significant unmet medical need.

“Advancing the clinical development of PRM-151, our lead product candidate, into clinical studies in myelofibrosis patients is a significant milestone for Promedior,” said Elizabeth G. Trehu, MD, FACP, Promedior’s Chief Medical Officer. “We are optimistic that data from this study, combined with the encouraging data in IPF, will demonstrate that PRM-151’s novel mechanism of action is applicable to a wide range of fibrotic diseases.”

 

Read the entire article at:

http://www.4-traders.com/news/Promedior-Initiates-Phase-2-Clinical-Study-of-PRM-151-in-Myelofibrosis–17336803/

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | 1 Comment

October 3 2013 – Newly identified biomarkers help predict outcome in deadly lung disease

New Haven, Conn. – A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational Medicine.

IPF causes progressive scarring of the lungs, leading to cough, shortness of breath, and potentially death. In most cases, the cause cannot be identified, and there is no cure other than a lung transplant. While some patients experience a progressive course that leads to death within one to two years, others experience a relative stable disease.

The researchers’ goal was to identify changes in expression of genes in the blood that are predictive of poor outcomes among patients with IPF.

Using two cohorts of patients, the researchers from Yale, University of Chicago, and University of Pittsburgh analyzed the expression of the genes in the whole genome of patients with IPF, and identified 52 genes that significantly correlated with outcome. They further found that the decreased expression of four genes — CD28, ICOS, LCK, and ITK — predicted shorter survival time in patients with IPF.

Read the entire article at:

http://www.eurekalert.org/pub_releases/2013-10/yu-nib100113.php

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

September 29 2013 – Trial to determine if stem cells can help with rare lung disease

By Cindy Krischer Goodman

cindykgoodman@gmail.com

Jose Guzman began gasping for breath while using his treadmill on the lowest setting and knew something was wrong. His search for answers led him to the diagnosis of a rare lung disease with no cure.

Guzman, 72, who arrived from Cuba penniless and built a thriving Miami travel agency, doesn’t give up easily. He has signed on to be one of the first patients to participate in a clinical trial being launched at the University of Miami. Dr. Marilyn Glassberg has obtained approval from the Food and Drug Administration to launch the first U.S. clinical trial that will test whether mesenchymal stem cells given intravenously could be a therapy for patients with Guzman’s rare lung disease, known as idiopathic pulmonary fibrosis. The disease strikes mostly men who are 55 and

Read the entire article at:

http://www.miamiherald.com/2013/09/28/3658088/trial-to-determine-if-stem-cells.html

 

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

September 28 2013 – Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

Abstract

During the past decade important progress has been made regarding the pathogenesis of idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic interstitial pneumonia with a median survival of 3 years. The knowledge gained has been used to design multicentre, randomised, placebo-controlled trials in order to investigate agents with different mechanisms of action. Encouraging results have led to licensing of the first IPF-specific drug, pirfenidone. However, the road to successful treatment is still long. The main aim for the future should be the careful design of clinical trials, by choosing the most clinically meaningful end-point and keeping in mind that combination of various agents may be more effective. This approach has been used in the treatment of lung cancer with which IPF presents many similarities.

 

Read the entire article at:

http://err.ersjournals.com/content/22/129/281.full

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

September 2 2013 – New pathway to treat colorectal cancer, pulmonary fibrosis

Israel researchers uncover secrets of how a certain white blood cell can flip from being a ‘good guy’ to a ‘bad guy’ in diseases with no current cure.

Doctoral student Danielle Karo-Atar studying macrophages at Tel Aviv University.

Doctoral student Danielle Karo-Atar studying macrophages at Tel Aviv University.

A type of white blood cell called a macrophage is one tricky customer. Expose macrophages to a certain stimulus and they’ll promote healing. But expose them to a different stimulus and they actually make the condition worse.

A team of Israeli researchers is making unprecedented progress in mapping the mechanism of these “good guy, bad guy” cells and understanding their role in the progression of two deadly diseases: colorectal cancer and idiopathic pulmonary fibrosis (IPF), an incurable lung condition.

Read the entire article at:

http://israel21c.org/health/new-pathway-to-treat-colorectal-cancer-pulmonary-fibrosis/

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

September 2 2013 – Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013

INGELHEIM, Germany–()–

For media outside the UK, US and Canada

  • Results of COPD Phase III landmark trial TIOSPIR™comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler®
  • Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD
  • Phase III data from MezzoTinA-asthma® trials evaluating the efficacy and safety of tiotropiumRespimat® in asthma patients symptomatic on moderate-dose maintenance inhaled corticosteroid (ICS) therapy
  • Results of LUX-Lung 6 Phase III trial demonstrating superiority of afatinibover standard chemotherapy in lung cancer patients with EGFR mutations1,2

Results from TIOSPIR(Tiotropium Safety and Performance in Respimat), one of the largest global chronic obstructive pulmonary disease (COPD) trials ever conducted, will       be presented for the first time at the Annual Congress of the European Respiratory Society (ERS), in Barcelona, Spain, September 7-11, 2013.

The highly anticipated three year TIOSPIRtrial assessed the relative safety and efficacy of the two marketed SPIRIVA® formulations –SPIRIVA® Respimat® Soft       Mist™ Inhaler 2.5 µg (once a day, 2 puffs§) versus SPIRIVA HandiHaler® 18 μg.** TIOSPIR included more than 17,000 COPD patients from 50 countries and, with broad inclusion criteria, featured a real-world study population that closely reflected the types of COPD patients physicians see every day. Boehringer Ingelheim is pleased to be sharing these results with the scientific community at the ERS Annual Congress, the largest respiratory meeting in the world.

Read the entire article at:

http://www.businesswire.com/news/home/20130901005010/en/Boehringer-Ingelheim-present-highly-anticipated-data-landmark

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

August 8 2013 – Aradigm Awarded NIH Grant to Investigate New Methods of Diagnoses of Aspirations of Gastrointestinal Contents into the Respiratory Tract with Scientists at UC San Francisco

HAYWARD, Calif.–(BUSINESS WIRE)–

The National Heart, Lung, and Blood Institute, National Institutes of  Health (NIH), awarded Aradigm Corporation (ARDM) a Small Business  Initiative Research (SBIR) grant to investigate the development and  validation of tests for gastro-esophageal reflux with aspirations into  the respiratory tract. The Principal Investigators and co-inventors of  the new diagnostic tests are Professor Homer Boushey, University of  California, San Francisco (UCSF) and Dr. Igor Gonda, Aradigm  Corporation. The grant of approximately $260,000 is funding laboratory  work and a human clinical trial to be conducted at UCSF.

Aspiration of gastric contents into the respiratory tract causes  significant morbidity and mortality and is accepted as the key  initiating event for aspiration pneumonitis – a form of acute lung  injury caused by the acidity of the gastric contents, and aspiration  pneumonia – the consequence of the growth of pathogenic bacteria  contained in the oropharynx aspirated into the tracheobronchial tree.  When subclinical events of gastric aspiration occur, it is described as   “silent aspiration” or “microaspiration.” Chronic, recurrent  microaspirations have been implicated in the pathogenesis and worsening  of many severe chronic pulmonary diseases of unknown origin, such  idiopathic pulmonary fibrosis, bronchiolitis obliterans after lung  transplantation, pulmonary disease in conditions associated with  esophageal dysfunction and delayed gastric emptying such as cystic  fibrosis and scleroderma, and the very common conditions of community  acquired pneumonia in the elderly, asthma and COPD.

Read the entire article at:

http://finance.yahoo.com/news/aradigm-awarded-nih-grant-investigate-110000078.html

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

August 5 2013 – Oral N-acetylcysteine (NAC) reduces COPD exacerbations in RCT (Chest)

Oxidative stress (imbalance between oxidants and antioxidants) is part of the story of how COPD causes symptoms of cough and shortness of breath. Cigarette smoke is the main source of oxidation damage in the lungs leading to COPD, but even after they quit smoking, people with COPD still have a so-called “redox imbalance” that contributes to their daily COPD symptoms.

N-acetylcysteine (NAC) is an antioxidant, anti-inflammatory, anti-mucus medicine that has already been tested in people with COPD as an oral drug. Also called Mucomyst, N-acetylcysteine was no blockbuster at preventing COPD exacerbations or improving symptoms — most trials did not show a benefit — but reviews and analyses have produced some optimism:

Read the entire article at:

http://pulmccm.org/2013/randomized-controlled-trials/n-acetylcysteine-reduces-copd-exacerbations-in-rct-chest/?art

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment